Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Significantly Enhanced High-Temperature Energy Storage Properties of Poly(ether imide) Dielectrics Enabled by Ultralow Content of Ni@Al<sub>2</sub>O<sub>3</sub> Nanofibers.

ACS applied materials & interfaces·2026
Same author

Correction: Li et al. Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation. <i>Molecules</i> 2023, <i>28</i>, 6035.

Molecules (Basel, Switzerland)·2026
Same author

Novel 1‑Phenyl-2,3-dihydroquinazolin-4(1H)-one Derivatives as Na<sub>v</sub> 1.8 Voltage-Gated Sodium Channels Inhibitors.

ACS medicinal chemistry letters·2026
Same author

Novel Pyrido[4,3‑<i>d</i>]pyrimidine Derivatives as Kirsten Rat Sarcoma (KRAS) G12C Potential Inhibitors.

ACS medicinal chemistry letters·2026
Same author

Novel Macrocyclic Compounds Targeting STING for Autoimmune Diseases Treatment.

ACS medicinal chemistry letters·2026
Same author

Novel Substituted Tetrahydropyrrolooxazolones as RIPK1 Inhibitors.

ACS medicinal chemistry letters·2026

Related Experiment Video

Updated: Mar 19, 2026

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.0K

Development and Validation of a Multicyclic Peptide Targeting PD-L1 for Radiotheranostics.

Lingxin Meng1, Xiaoyan Li1, Jimmy S Patel1,2

  • 1Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.

ACS Medicinal Chemistry Letters
|March 18, 2026
PubMed
Summary
This summary is machine-generated.

New peptide imaging agents show promise for visualizing programmed cell death protein 1 (PD-1) expression in vivo. This could improve patient selection for immunotherapy by overcoming limitations of current imaging methods.

Keywords:
CancerDisulfide-directed multicyclic peptide (DDMP)Positron emission tomography (PET)Programmed death-ligand 1 (PD-L1)Radiotheranostics

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.4K

Related Experiment Videos

Last Updated: Mar 19, 2026

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.0K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.4K

Area of Science:

  • Oncology
  • Molecular Imaging
  • Immunotherapy

Background:

  • Immune checkpoint inhibitors targeting PD-1/PD-L1 axis have transformed cancer treatment.
  • Current methods like immunohistochemistry for PD-L1 assessment lack dynamic, whole-body information.
  • Existing positron emission tomography (PET) tracers for PD-L1 imaging face challenges with tumor uptake and pharmacokinetics.

Purpose of the Study:

  • To develop novel imaging agents for visualizing PD-L1 expression in vivo.
  • To overcome limitations of current PD-L1 imaging techniques for patient stratification in cancer therapy.

Main Methods:

  • Development of a disulfide-directed multicyclic peptide (DDMP) platform.
  • Generation of high-affinity peptide ligands targeting PD-L1.

Main Results:

  • The DDMP platform successfully generated peptide ligands with potential for PD-L1 imaging.
  • These ligands are designed to improve upon existing radiotracers for PD-L1 visualization.

Conclusions:

  • The DDMP platform offers a promising strategy for developing advanced PD-L1 imaging agents.
  • This approach could enhance patient stratification for PD-1/PD-L1 blockade immunotherapy.